ReNerve

ASX Announcement
28 August 2026

ReNerve Delivers Record FY26 Sales Growth and Advances Global Expansion Strategy

Key Highlights

- FY26 sales revenue up 88% to $510k (FY25: $272k), reflecting accelerating adoption of the Company's products across targeted markets.
- Record June quarter sales of $211k, representing the strongest quarterly sales result in the Company's history.
- Successfully completed a $3.2 million capital raising to support commercial expansion and product development initiatives.
- Expanded international regulatory footprint with approvals for NervAlign® Nerve Cuff in Malaysia, Hong Kong, India, Indonesia and the Philippines.
- Launched the Empliq™ human tissue product range and achieved first commercial sales.
- Expanded United States distribution network to 21 distribution partners.
- Secured purchasing approvals across United States Department of Defense and Veterans Affairs healthcare systems, significantly broadening hospital market access.
- Continued positive momentum in the Company's clinical program, building upon previously announced statistically significant interim study results.
- Advanced development of both the NervAlign® Nerve Conduit and NervAlign® Nerve Guide Matrix programs toward future commercialisation milestones.
- Post year-end secured a funding facility of up to A$5 million with RiverFort to support ongoing growth initiatives.
- Received marketing approval (registration) for NervAlign® Nerve Cuff in the Philippines – the second most populous nation in Southeast Asia with over 115 million people — one of the largest single-country opportunities in ReNerve's regional strategy.
- Grows Asia-Pacific footprint alongside the United States, New Zealand, Hong Kong, Thailand, Malaysia and Indonesia.

- The Asia-Pacific nerve repair market is estimated to be worth around USD $100 million in 2026[1], with the Philippines' large population and high burden of trauma- and diabetes-related nerve injury making it a strategically significant market.

FY26 Performance

ReNerve Limited (ASX, "**ReNerve**" or "**the Company**"), an Australian biotechnology company developing innovative products for peripheral nerve injury ("PNI") repair, delivered a transformational year during FY26, achieving strong revenue growth while significantly expanding its commercial footprint, product portfolio and regulatory reach.

Revenue increased 88% to $510,357, driven primarily by increased utilisation of the Company's flagship NervAlign® Nerve Cuff product in the United States and the successful introduction of the Empliq™ tissue product range.

Sales momentum accelerated throughout the financial year, increasing from $66k in the September quarter to a record $211k in the June quarter, demonstrating growing surgeon adoption and strengthening distribution channel effectiveness.

The Company reported a net loss after tax of $5.57 million, reflecting continued investment in commercialisation activities, expansion of the management and sales infrastructure, ongoing clinical studies and advancement of the product development pipeline.

Cash and cash equivalents at 30 June 2026 were $1.49 million, supported by a $3.2 million equity raising completed during the year and receipt of a $517k R&D Tax Incentive refund.

Commercial Progress

During FY26, ReNerve continued executing its strategy of becoming a diversified regenerative medicine business focused on peripheral nerve repair and adjacent biologic solutions.

The Company expanded its US market presence substantially through the growth of its distribution network to 21 partners and secured access to the Department of Defense and Veterans Affairs procurement systems, opening a significant number of additional treatment facilities to the NervAlign® Nerve Cuff.

The launch of the Empliq™ product range broadened ReNerve's commercial offering and enabled greater leverage of existing distribution relationships.

Product Development and Clinical Progress

The Company continued advancing its next generation peripheral nerve repair portfolio.

Key milestones achieved during FY26 included:

- Commercial scale-up activities for the NervAlign® Nerve Conduit ahead of planned market launch activities.

[1] Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

- Progression of the NervAlign® Nerve Guide Matrix program to Stage 3 manufacturing development.
- Ongoing recruitment into the Company's clinical study, following previously reported statistically significant interim results demonstrating superior patient outcomes.

The Company believes these programs provide a pathway to establishing a comprehensive product platform across multiple segments of the peripheral nerve repair market.

International Expansion

ReNerve made substantial progress executing its international growth strategy.

During and immediately following FY26, the Company achieved regulatory approvals for NervAlign® Nerve Cuff in:

- Malaysia
- Hong Kong
- India
- Indonesia
- Philippines

These approvals substantially increase ReNerve's addressable market opportunity across the Asia-Pacific region and support the Company's strategy of building a global nerve repair platform.

Chair, Maja McGuire said:

"FY26 represented a pivotal year for ReNerve. We delivered record sales growth, strengthened our commercial infrastructure, expanded into new international markets and advanced our product pipeline toward future commercialisation milestones. The Board believes the foundations established during the year position the Company to pursue significant long-term growth opportunities within the global nerve repair market."

Outlook

ReNerve enters FY27 with increasing sales momentum, a broader commercial product portfolio, expanded market access and a growing international presence.

Management remains focused on:

- Accelerating adoption of NervAlign® products in the United States;
- Commercialising newly approved international markets;
- Expanding the Empliq™ tissue product range;
- Progressing the NervAlign® Nerve Conduit and Nerve Guide Matrix development programs; and
- Driving revenue growth while maintaining disciplined capital management.

- ENDS -

This announcement has been approved for release by the Company's Board of Directors.

For further information and enquiries, please contact:

Dr Julian Chick
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

Matthew Wright
Investor & Media Relations
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au

About ReNerve Limited (ASX:RNV)

ReNerve Limited (ASX:RNV) is transforming nerve repair and improving lives through breakthrough medical technology. Founded by a neurosurgeon and medtech researchers, ReNerve is a rapidly growing medical device company that has revolutionised peripheral nerve surgery with its innovative, ready-to-use solutions for peripheral nerve injuries (PNI). Our scientifically backed products are delivering measurably better outcomes for patients worldwide.

Proven Clinical Success

ReNerve's first flagship product, the FDA-cleared **NervAlign® Nerve Cuff**, is already making a dramatic difference in surgical outcomes across the United States. A recently announced clinical study has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement that's changing lives.

Comparison of Patient Pre & Post Surgery Pain Score



Standard of Care vs NervAlign™ Nerve Cuff Protected Nerve Repairs

The comparison of pain scores between the two cohorts of patients

Comprehensive Product Portfolio

ReNerve is advancing a complete suite of nerve repair solutions and related surgical repairs:

On market

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Empliq™ Dermal tissue product --** A unique deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Empliq™ Amniotic tissue product ranges --** Three amniotic tissue product ranges used to aid the healing of wounds.

In development

- **NervAlign® Nerve Conduit Range –** Next-generation nerve conduit leveraging advantages of eCOO technology in a material designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – a customised and ready-to-use alternative to existing nerve grafts, for treatment of longer nerve gaps and more severe nerve injuries. It will eliminate the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

Market Leadership and Growth

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales and YTD FY2026 sales revenues showing further significant increases across its portfolio. Our high-margin, scalable products are positioning us as the go-to solution for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.6 billion in 2024 and is projected to reach $6.2 billion by 2031.[2]

Vision and Values

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.

[2] Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)